{"id":"pep005-ingenol-mebutate-gel","safety":{"commonSideEffects":[{"rate":"80–90","effect":"Local skin irritation (erythema, flaking, crusting)"},{"rate":"50–70","effect":"Application site pain or burning"},{"rate":"20–40","effect":"Pruritus"},{"rate":"10–30","effect":"Edema"},{"rate":"10–20","effect":"Vesiculation or pustulation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug works through a dual mechanism: direct cytotoxic effects via PKC activation leading to cell death in treated lesions, and activation of local immune responses including neutrophil infiltration and antibody-dependent cellular cytotoxicity. This combination results in both immediate destruction of visible lesions and immunological elimination of subclinical disease in the surrounding skin.","oneSentence":"Ingenol mebutate activates protein kinase C (PKC) to induce rapid necrosis of actinic keratosis cells and trigger immune-mediated clearance of remaining lesions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:07.996Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis (field treatment on face or scalp)"}]},"trialDetails":[{"nctId":"NCT02723721","phase":"PHASE2","title":"Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2016-06-15","conditions":"Lentigo Maligna","enrollment":20},{"nctId":"NCT01820260","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-04","conditions":"Actinic Keratosis","enrollment":395},{"nctId":"NCT01541553","phase":"PHASE3","title":"A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-03","conditions":"Actinic Keratosis","enrollment":367},{"nctId":"NCT01998984","phase":"PHASE2","title":"Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-01","conditions":"Actinic Keratosis","enrollment":266},{"nctId":"NCT02361216","phase":"PHASE3","title":"Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Actinic Keratosis","enrollment":729},{"nctId":"NCT01600014","phase":"PHASE3","title":"Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Actinic Keratosis","enrollment":463},{"nctId":"NCT01449513","phase":"PHASE1","title":"PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-09","conditions":"Actinic Keratosis","enrollment":24},{"nctId":"NCT01926496","phase":"PHASE4","title":"Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-09-11","conditions":"Actinic Keratosis (AK)","enrollment":485},{"nctId":"NCT01703078","phase":"PHASE1","title":"Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-11","conditions":"Actinic Keratosis","enrollment":41},{"nctId":"NCT01892137","phase":"PHASE1","title":"Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-07","conditions":"Actinic Keratosis","enrollment":137},{"nctId":"NCT01387711","phase":"PHASE1","title":"PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-08","conditions":"Actinic Keratosis","enrollment":27},{"nctId":"NCT02124239","phase":"PHASE1","title":"Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-04","conditions":"Actinic Keratosis","enrollment":79},{"nctId":"NCT01803477","phase":"PHASE1, PHASE2","title":"Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-02","conditions":"Actinic Keratosis","enrollment":37},{"nctId":"NCT01787383","phase":"PHASE3","title":"A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-02","conditions":"Actinic Keratosis","enrollment":200},{"nctId":"NCT02406014","phase":"PHASE4","title":"Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Actinic Keratosis (AK)","enrollment":502},{"nctId":"NCT03546166","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2018-07-26","conditions":"Carcinoma","enrollment":24},{"nctId":"NCT04202445","phase":"","title":"TreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl Mebutate Gel (Picato®) on Patients Satisfaction","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-04","conditions":"Actinic Keratosis","enrollment":1218},{"nctId":"NCT03336372","phase":"EARLY_PHASE1","title":"Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients","status":"WITHDRAWN","sponsor":"Center for Clinical Studies, Texas","startDate":"2017-12-20","conditions":"Molluscum Contagiosum","enrollment":""},{"nctId":"NCT02866695","phase":"PHASE4","title":"Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-10-06","conditions":"Actinic Keratosis","enrollment":20},{"nctId":"NCT02459795","phase":"PHASE3","title":"To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2015-05","conditions":"Actinic Keratosis","enrollment":469},{"nctId":"NCT02385318","phase":"PHASE3","title":"To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2015-02","conditions":"Actinic Keratosis","enrollment":519},{"nctId":"NCT02654769","phase":"PHASE3","title":"A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-02","conditions":"Actinic Keratosis","enrollment":441},{"nctId":"NCT03200912","phase":"PHASE3","title":"An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-08-19","conditions":"ACTINIC KERATOSIS","enrollment":507},{"nctId":"NCT02421471","phase":"","title":"PMS to Evaluate the Safety and Efficacy of Picato® Gel","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-09","conditions":"Actinic Keratosis","enrollment":1324},{"nctId":"NCT03452566","phase":"PHASE1, PHASE2","title":"Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment","status":"WITHDRAWN","sponsor":"Instituto Nacional de Cancer, Brazil","startDate":"2020-02","conditions":"Actinic Cheilitis","enrollment":""},{"nctId":"NCT02354391","phase":"PHASE2","title":"Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis","status":"UNKNOWN","sponsor":"Pacific Dermaesthetics","startDate":"2015-01","conditions":"Actinic Keratosis","enrollment":20},{"nctId":"NCT02594436","phase":"","title":"The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-12-01","conditions":"Actinic Keratosis","enrollment":440},{"nctId":"NCT02473848","phase":"PHASE3","title":"Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses","status":"TERMINATED","sponsor":"Günther Hofbauer","startDate":"2015-06","conditions":"Actinic Keratosis","enrollment":3},{"nctId":"NCT03508856","phase":"NA","title":"Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin","status":"COMPLETED","sponsor":"Skin Laser & Surgery Specialists","startDate":"2015-11-09","conditions":"Actinic Keratosis, Photo-aged Skin","enrollment":23},{"nctId":"NCT02716714","phase":"PHASE4","title":"Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis","status":"COMPLETED","sponsor":"Korea University","startDate":"2015-04","conditions":"Actinic Keratosis","enrollment":77},{"nctId":"NCT02748902","phase":"PHASE1","title":"Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.","status":"COMPLETED","sponsor":"Neal D. Bhatia, MD","startDate":"2016-04-27","conditions":"Verruca Vulgaris, Common Warts","enrollment":16},{"nctId":"NCT02251652","phase":"PHASE4","title":"Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2013-04","conditions":"Actinic Keratoses","enrollment":16},{"nctId":"NCT02411851","phase":"PHASE1","title":"Treatment of Actinic Keratoses (AK) on the Face","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2015-03","conditions":"Actinic Keratoses","enrollment":20},{"nctId":"NCT00357916","phase":"PHASE1","title":"Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test Design","status":"COMPLETED","sponsor":"Peplin","startDate":"2006-06","conditions":"Healthy","enrollment":200},{"nctId":"NCT01325688","phase":"PHASE2","title":"PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities","status":"COMPLETED","sponsor":"Peplin","startDate":"2011-04","conditions":"Superficial Basal Cell Carcinoma","enrollment":75},{"nctId":"NCT00432185","phase":"PHASE2","title":"To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC","status":"COMPLETED","sponsor":"Peplin","startDate":"2007-02","conditions":"Superficial Basal Cell Carcinoma","enrollment":117},{"nctId":"NCT00375739","phase":"PHASE2","title":"Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses","status":"COMPLETED","sponsor":"Peplin","startDate":"2006-09","conditions":"Actinic Keratosis","enrollment":200},{"nctId":"NCT00546611","phase":"PHASE1","title":"The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)","status":"WITHDRAWN","sponsor":"Peplin","startDate":"2007-10","conditions":"Warts","enrollment":""},{"nctId":"NCT00427050","phase":"PHASE2","title":"A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel","status":"COMPLETED","sponsor":"Peplin","startDate":"2007-01","conditions":"Actinic Keratoses","enrollment":50},{"nctId":"NCT01302925","phase":"PHASE1","title":"PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects","status":"COMPLETED","sponsor":"Peplin","startDate":"2011-02","conditions":"Healthy, Actinic Keratosis","enrollment":100},{"nctId":"NCT00659893","phase":"PHASE1","title":"Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2","status":"COMPLETED","sponsor":"Peplin","startDate":"2008-04","conditions":"Actinic Keratosis","enrollment":64},{"nctId":"NCT00850681","phase":"PHASE1","title":"A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-02","conditions":"Actinic Keratosis","enrollment":50},{"nctId":"NCT00850811","phase":"PHASE1","title":"A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-02","conditions":"Actinic Keratosis","enrollment":30},{"nctId":"NCT00917306","phase":"PHASE3","title":"A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-06","conditions":"Actinic Keratosis","enrollment":102},{"nctId":"NCT00700063","phase":"PHASE2","title":"A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","status":"COMPLETED","sponsor":"Peplin","startDate":"2008-06","conditions":"Actinic Keratosis","enrollment":265},{"nctId":"NCT00544297","phase":"PHASE2","title":"A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand","status":"COMPLETED","sponsor":"Peplin","startDate":"2007-10","conditions":"Actinic Keratosis","enrollment":12},{"nctId":"NCT00916006","phase":"PHASE3","title":"A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-06","conditions":"Actinic Keratosis","enrollment":269},{"nctId":"NCT00239135","phase":"PHASE2","title":"Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel","status":"COMPLETED","sponsor":"Peplin","startDate":"2005-09","conditions":"Keratosis","enrollment":34},{"nctId":"NCT00107965","phase":"PHASE2","title":"Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses","status":"COMPLETED","sponsor":"Peplin","startDate":"2005-03","conditions":"Actinic Keratosis","enrollment":60},{"nctId":"NCT00742391","phase":"PHASE3","title":"A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","status":"COMPLETED","sponsor":"Peplin","startDate":"2008-09","conditions":"Actinic Keratoses","enrollment":255},{"nctId":"NCT00915551","phase":"PHASE3","title":"A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-06","conditions":"Actinic Keratosis","enrollment":278},{"nctId":"NCT00942604","phase":"PHASE3","title":"A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-07","conditions":"Actinic Keratoses","enrollment":203},{"nctId":"NCT00852137","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-03","conditions":"Actinic Keratosis","enrollment":16},{"nctId":"NCT00544258","phase":"PHASE1","title":"Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005","status":"COMPLETED","sponsor":"Peplin","startDate":"2007-10","conditions":"Actinic Keratoses","enrollment":8},{"nctId":"NCT00108121","phase":"PHASE2","title":"Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Peplin","startDate":"2005-03","conditions":"Basal Cell Carcinoma","enrollment":60},{"nctId":"NCT00329121","phase":"PHASE2","title":"Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ","status":"COMPLETED","sponsor":"Peplin","startDate":"2006-05","conditions":"Carcinoma, Squamous Cell","enrollment":24},{"nctId":"NCT02242747","phase":"NA","title":"Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2014-05","conditions":"Actinic Keratosis","enrollment":100},{"nctId":"NCT01836367","phase":"PHASE1","title":"Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2013-03","conditions":"Actinic Keratosis","enrollment":20},{"nctId":"NCT01214577","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin","status":"COMPLETED","sponsor":"Peplin","startDate":"2010-10","conditions":"Photo-damage","enrollment":24},{"nctId":"NCT01214564","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis","status":"COMPLETED","sponsor":"Peplin","startDate":"2010-10","conditions":"Seborrheic Keratosis","enrollment":24},{"nctId":"NCT00108134","phase":"PHASE2","title":"Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Peplin","startDate":"2005-03","conditions":"Basal Cell Carcinoma","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":86,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PEP005 (ingenol mebutate) Gel","genericName":"PEP005 (ingenol mebutate) Gel","companyName":"Peplin","companyId":"peplin","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ingenol mebutate activates protein kinase C (PKC) to induce rapid necrosis of actinic keratosis cells and trigger immune-mediated clearance of remaining lesions. Used for Actinic keratosis (field treatment on face or scalp).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}